VBWG - Online Lectures

Updated: May 09, 2008

Options

     This area of the site
     requires the Adobe
     Acrobat Reader and
     a Media Player.
     Click below to
     download the
     software now.

Conference highlights and audio downloads.

Release Date		Meeting Title
Apr 28 2008		NEW! Leading the Way in Cardiovascular Regenerative Medicine Carl J. Pepine, MD, MACC University of Florida College of Medicine Gainesville, Florida
Mar 25 2008 Orlando, Florida		Global CV Risk Management: Is it Practical? JoAnne M. Foody, MD, FACC, FAHA Yale University School of Medicine
Mar 18 2008 San Francisco, California		Lifestyle Modification and the Patient with Complicated Hypertension C. Noel Bairey Merz, MD Cedars-Sinai Medical Center
Mar 07 2008 Orlando, Florida		Progress and Promise in RAAS Blockade Carl J. Pepine, MD, MACC University of Florida College of Medicine
Feb 15 2008 Chicago, Illinois		Parenteral Treaments in Acute Hypertension Jerrold Levy, MD, FAHA Emory University School of Medicine
Jan 28 2008 New York, NY		Understanding Chronic Ischemic Heart Disease Today Robert L. Wilensky, MD, FACC University of Pennsylvania Health System
Dec 26 2007 Irving, CA		Risk Stratification in Patients with Chronic Myocardial Ischemia William S. Weintraub, MD, FACC Christiana Care Health System
Nov 27 2007 Irving, TX		Understanding Chronic CAD: Flow-Limiting Obstruction vs Vulnerable Plaque Peter H. Stone, MD, FACC, FAHA Harvard Medical School
Nov 15 2007 Dallas, TX		Insights on the Interaction of Antiarrhythmia Therapy and Ischemia Peter R. Kowey, MD, FACC Jefferson Medical College
Oct 25 2007 Dallas, TX		Ischemic Heart Disease Risk Management in Women: Recent Evidence C. Noel Bairey Merz, MD, FACC Cedars-Sinai Medical Center
Oct 22 2007 Orlando, FL		Pathophysiology of Atherogenic Dyslipidemia Ronald M. Krauss, MD University of California, Berkeley
Oct 10 2007 Irving, Texas		Winning CV and Metabolic Parameters Carl J. Pepine, MD, MACC University of Florida College of Medicine
Sep 26 2007 Houston, TX		Intensive Glycemic Control and CV Risk Reduction Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP William Beaumont Hospital
Sep 19 2007 Irving, Texas		Angina and Ischemia Reduction: Trial Update Benjamin M. Scirica, MD, MPH Harvard Medical School
Sep 12 2007 Houston, Texas		Impact of Hyperglycemia at the Vessel Wall Ajay Chaudhuri, MBBS, MRCP, FACE Diabetes - Endocrinology Center of Western New York
Aug 15 2007 New York, New York		Assessing Global Cardiovascular and Diabetes Risk: Targeting Abdominal Adiposity Robert E. Heinig, MD Rochester General Hospital
Aug 08 2007 New York, New York		Intensive Glycemic Control and CV Risk Reduction Stuart W. Zarich, MD, FACC, FASE Yale University School of Medicine
Aug 01 2007 Orlando, Florida		Clinical Imperatives for Treating ACS Patients with Diabetes Darren K. McGuire, MD, MHSc, FACC Parkland Health and Hospital System
Jul 25 2007 Orlando, Florida		Glycemic Control and Patient Outcomes: Clinical Trial Overview Robert E. Heinig, MD Rochester General Hospital
Jul 18 2007 Atlanta, Georgia		Recent Insights on Abdominal Adiposity and CV Risk Ori Ben-Yehuda, MD, FACC University of California, San Diego
Jul 12 2007 Orlando, Florida		Prognostic Importance of Hyperglycemia in Coronary Events JoAnne M. Foody, MD, FACC Yale University School of Medicine
Jul 03 2007 Detroit, Michigan		Role of Glucose Control in CV Risk Modification Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP William Beaumont Hospital
Jun 27 2007 Orlando, Florida		Hyperglycemia in Acute Coronary Syndromes Ira J. Goldberg, MD Columbia University College of Physicians and Surgeons
Jun 20 2007 Orlando, Florida		Residual CV Risk and Future Treatment Strategies Deepak L. Bhatt, MD, FACC, FESC, FSCAI, FACP Cleveland Clinic Lerner College of Medicine
Jun 13 2007 Chicago, Illinois		Assessing Global Cardiovascular and Diabetes Risk: Targeting Abdominal Adiposity Howard S. Weintraub, MD, FACC New York University School of Medicine
Jun 06 2007 Orlando, Florida		Implications of CB₁ Blockade for the Cardiologist Andrew P. Selwyn, MD, FRCP, FACC Harvard Medical School
May 30 2007 Orlando, Florida		Impact of Insulin Resistance on Cardiometabolic Risk Theodore Mazzone, MD, FACP, FAHA University of Illinois College of Medicine
May 21 2007 New Orleans, Louisiana		The RUTH Trial: Estrogen Receptor Modulation and CV Events Elizabeth L. Barrett-Connor, MD University of California, San Diego, School of Medicine
May 16 2007 Orlando, Florida		Adiposity in Cardiovascular Risk Reduction Jorge Plutzky, MD, FACC, FAHA Harvard Medical School
May 09 2007 New Orleans, Louisiana		The New NHLBI CV Cell Therapy Research Network Robert D. Simari, MD Mayo Clinic College of Medicine
May 02 2007 Nashville, Tennessee		Reducing Cardiovascular Morbidity and Mortality Through RAAS Modulation: New Trial Data Eva M. Lonn, MD, MSc, FRCPC, FACC Hamilton Health Sciences
Apr 25 2007 Short Hills, New Jersey		Inhibiting Angiotensin II at the Vessel Wall: Impact on Atherosclerosis Robert L. Wilensky, MD, FACC University of Pennsylvania School of Medicine
Apr 18 2007 New Orleans, Louisiana		The Cardiovascular Disease Continuum: Trends, Lessons, and a Look to the Future Victor J. Dzau, MD Duke University Medical Center
Apr 12 2007 Gaithersburg, Maryland		Long-Term Effects on Arterial Healing with DES Renu Virmani, MD, FACC CVPath Institute, Inc.
Mar 29 2007 Royal Oak, Michigan		Clinical Imperatives for Treating Patients with Diabetes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP William Beaumont Hospital
Mar 07 2007 Chicago, Illinois		Vascular Protection and CB1 Blockade: Evolving Data Jean-Pierre Després, PhD, FAHA Laval Hospital Research Centre Laval University
Feb 28 2007 Chicago, Illinois		The Apelin System and Potential Therapeutic Applications Douglas E. Vaughan, MD, FACC Vanderbilt University Medical Center
Feb 13 2007 Québec City, Québec, Canada		ACE Inhibition and Vascular Disease: Recent Insights Gilles R. Dagenais, MD Québec Heart Institute Laval University
Jan 24 2007 Seattle, Washington		New Therapeutic Options for the Treatment of Chronic Angina David A. Morrow, MD, MPH, FACC, FAHA Harvard Medical School
Jan 17 2007 Orlando, Florida		Estrogen and RAAS: New Mechanistic Insights Paula J. Harvey, MD, PhD University of Toronto
Jan 10 2007 Irving, Texas		A Diabetes Outcome Prevention Trial Steven M. Haffner, MD, MPH, FACP University of Texas Health Science Center
Jan 03 2007 Toronto, Ontario, Canada		Do Angiotensin Receptor Blockers Increase the Risk of Myocardial Infarction? Martin H. Strauss, MD, FRCPC, FACC North York General Hospital
Dec 20 2006 La Jolla, California		Should the Use of Drug Eluting Stents Be Routine in Patients with Acute Coronary Syndromes? Jeffrey J. Popma, MD Harvard Medical School
Dec 11 2006 Chicago, Illinois		Update on Efficacy in Acute Myocardial Infarction with DES Frans Van de Werf, MD, PhD University Hospital Gasthuisberg Leuven, Belgium
Dec 07 2006 Chicago, Illinois		Long-Term Effects on Arterial Healing with DES Renu Virmani, MD, FACC CVPath Institute, Inc.
Nov 30 2006 Chicago, Illinois		Imaging Modalities for Stem Cell Therapy Joseph C. Wu, MD, PhD Stanford University School of Medicine
Nov 28 2006 Chicago, Illinois		The Promise of Stem Cell Therapies Douglas W. Losordo, MD Northwestern University Medical School
Nov 21 2006 Chicago, Illinois		Scientific and Mechanistic Rationale for the MERLIN Study Bernard R. Chaitman, MD, FRCPC, FACC, FAHA Saint Louis University School of Medicine
Nov 17 2006 Chicago, Illinois		Gene Analysis of Cardiac Transplanted Cells Amit N. Patel, MD, MS University of Pittsburgh Medical Center
Nov 14 2006 Chicago, Illinois		Qualitative Changes of HDL in Metabolic Syndrome – Impact on Vasoprotective Properties Ulf Landmesser, MD Medizinische Hochschule Hannover
Nov 01 2006 Houston, Texas		Vascular Consequences of Diabetes and Insulin Resistance Darren K. McGuire, MD, FACC, FACP University of Texas Southwestern Medical Center at Dallas
Oct 16 2006 Orlando, Florida		Vascular Biology: Progress and Promise in Cardiovascular Disease Management Carl J. Pepine, MD, MACC University of Florida College of Medicine
Oct 11 2006 Marina del Rey, California		CV Risk Reduction, Diabetes Prevention, and TZDs Jeffrey L. Probstfield, MD, FACC, FACP University of Washington School of Medicine
Sep 18 2006 New York, New York		Placing Renal Disease In Perspective Gerald B. Appel, MD Columbia University College of Physicians and Surgeons
Sep 08 2006 New York, New York		The Diabetes Pandemic: Urgent Need for Prevention Jeffrey L. Probstfield, MD, FACC, FACP University of Washington School of Medicine
Aug 09 2006 San Francisco, California		Clinical Implications of Insulin Resistance Willa A. Hsueh, MD David Geffen School of Medicine at UCLA
Aug 02 2006 Philadelphia, Pennsylvania		Clinical Imperatives for Treating Patients with Diabetes Peter N. Weissman, MD, FACE, FACP University of Miami School of Medicine
Jul 21 2006 Atlanta, Georgia		Vascular Consequences of Diabetes and Insulin Resistance Andrew P. Selwyn, MD, FRCP, FACC Harvard Medical School
Jul 12 2006 Houston, Texas		Practical Considerations in the Management of Patients with Chronic Ischemic Heart Disease Robert L. Wilensky, MD, FACC University of Pennsylvania School of Medicine
Jul 05 2006 Boston, Massachusetts		Novel Approaches in Chronic Myocardial Ischemia Peter H. Stone, MD, FACC, FAHA Harvard Medical School
Jun 16 2006 Marina del Rey, California		New Therapeutic Options for Treating Chronic Myocardial Ischemia David A. Morrow, MD, MPH, FACC, FAHA Harvard Medical School
Jun 07 2006 St. Louis, Missouri		Case-Study: Optimizing Clinical Outcomes in Myocardial Ischemia Moderator: Bernard R. Chaitman, MD, FRCPC, FACC, FAHA Discussants: Robert W. Biederman, MD, FACC, FASA Jerome D. Cohen, MD, FACC, FACP
May 31 2006 St. Louis, Missouri		Practical Considerations in the Management of Patients with Chronic Ischemic Heart Disease Jerome D. Cohen, MD, FACC, FACP Saint Louis University School of Medicine
May 24 2006 Brooklyn, New York		Halting Cardiovascular Disease Progression in Patients with Multiple Risk Factors Gerald B. Appel, MD Columbia University College of Physicians and Surgeons
May 24 2006 New York, New York		Myocardial Ischemia: View from the Vessel Wall Andrew P. Selwyn, MD, FRCP, FACC Harvard Medical School
Apr 20 2006 Philadelphia, Pennsylvania		New Therapies to Improve Outcomes in Patients with Multiple CV Risks Robert A. Vogel, MD University of Maryland School of Medicine
Apr 20 2006 Cincinnati, Ohio		Identifying Candidates at High Risk of Cardiovascular Disease Roy C. Blank, MD The Presbyterian Cardiovascular Institute
Apr 12 2006 Orlando, Florida		Diabetes Pandemic: Prevention Urgently Needed Jeffrey L. Probstfield, MD, FACC, FACP University of Washington School of Medicine
Mar 29 2006 St. Petersburg, Florida		Contemporary Strategies for Managing Myocardial Ischemia Bernard R. Chaitman, MD Saint Louis University School of Medicine
Mar 21 2006 Atlanta, Georgia		Intramyocardial Transplantation of Autologous CD34+ Cells for Intractable Angina Douglas W. Losordo, MD Tufts University School of Medicine
Mar 16 2006 St. Petersburg, Florida		New Mechanistic Insights in Ischemia and Coronary Supply Peter H. Stone, MD Harvard Medical School
Mar 03 2006 Chicago, Illinois		Tailoring Antithrombotic Therapies Lloyd W. Klein, MD Rush Medical College
Mar 01 2006 Coral Gables, Florida		Negative Effects of Insulin Resistance on the Vessel Wall Darren K. McGuire, MD, FACC, FACP University of Texas Southwestern Medical Center at Dallas
Feb 24 2006 Princeton, New Jersey		Halting Cardiovascular Disease Progression in Patients with Multiple Risk Factors Gerald B. Appel, MD Columbia University College of Physicians and Surgeons
Feb 22 2006 Philadelphia, Pennsylvania		Antiplatelet Strategies in ACS: Clinical Trial Data Robert L. Wilensky, MD, FACC University of Pennsylvania School of Medicine
Feb 17 2006 Philadelphia, Pennsylvania		The Role of Platelets in Atherothrombosis Richard C. Becker, MD Duke University Medical Center
Feb 10 2006 La Jolla, California		The Role of Platelets in Atherothrombosis Andrew P. Selwyn, MD, FRCP, FACC Harvard Medical School
Feb 03 2006 Washington, DC		An Update on Therapeutic Interventions Against Platelet Activation and Aggregation Robert P. Giugliano, MD, SM Harvard Medical School
Feb 03 2006 Washington, DC		Early, Comprehensive Management of ACS: Perspectives on New Trial Data William E. Boden, MD, FACC University of Connecticut School of Medicine
Feb 03 2006 McLean, Virginia		Treatment Strategies for Halting the Progression of CVD in High Risk Patients James R. Sowers, MD, FACE, FACP University of Missouri-Columbia
Jan 23 2006 New York, New York		Treatment Strategies for Halting the Progression of CVD in High Risk Patients Samuel Dagogo-Jack, MD, FRCP University of Tennessee College of Medicine
Dec 21 2005 Washington, DC		The CRUSADE Registry: Status Report Eric D. Peterson, MD, MPH, FACC, FAHA Duke University Medical Center
Dec 16 2005 Orlando, Florida		Impact of Recent Clinical Trials on Optimal Lipid Goals Robert A. Vogel, MD University of Maryland School of Medicine
Dec 06 2005 Dearborn, Michigan		Biomarkers of Cardiovascular Disease: Traditional and Emerging Concepts Arshed A. Quyyumi, MD, FACC, FRCP Emory University School of Medicine
Oct 27 2005 Phoenix, Arizona		New Data and Directions in the Treatment of Coronary Artery Disease Carl J. Pepine, MD, MACC University of Florida College of Medicine
Oct 19 2005 St. Louis, Missouri		Should All Coronary Artery Disease Patients be Given an ACE Inhibitor? Jerome D. Cohen, MD, FACC, FACP Saint Louis University
Oct 06 2005 Cleveland, Ohio		Negative Effects of Insulin Resistance on the Vessel Wall Andrew P. Selwyn, MD, FRCP, FACC Harvard Medical School
Aug 29 2005 New York, New York		Implementing Treatment Guidelines in Clinical Practice Robert E. Heinig, MD University of Rochester Medical School
Aug 18 2005 Atlanta, Georgia		EUROPA in the Context of HOPE and PEACE Willem J. Remme, MD, PhD, FESE, FACC, FAHA Sticares Cardiovascular Research Foundation
Aug 09 2005 Chicago, Illinois		Clinical Update: Should All CAD Patients be Treated With an ACE Inhibitor? Eva Lonn, MD, MSc, FRCPC, FACC McMaster University
Jul 25 2005 Amelia Island, Florida		Central Role of Fat on Progression of Insulin Resistance and Cardiovascular Disease: New Data Willa A. Hsueh, MD University of California, Los Angeles
Jun 17 2005 Orlando, Florida		RAAS Modulation in the Atherosclerotic process: Mechanistic insights Howard R. Horn, MD, FACC, FACP, FAHA The University of Tennessee Health Science Center
May 12 2005 Orlando, Florida		Endothelial Dysfunction and Repair: Potential Role for Endothelial Progenitor Cells Arshed A. Quyyumi, MD, FRCP, FACC Emory University School of Medicine
May 06 2005 Orlando, Florida		The Mediterranean Diet: Ideal Cardiovascular Diet? James H. O'Keefe, Jr, MD, FACC University of Missouri - Kansas City Medical School
Mar 04 2005 Philadelphia, Pennsylvania		Vascular benefits of ACE inhibition: An update Andrew P. Selwyn, MD Harvard Medical School
Dec 16 2004 Philadelphia, Pennsylvania		Optimizing CAD protection: New trial data Eva Lonn, MD, MSc, FRCPC, FACC McMaster University
Dec 14 2004 Houston, Texas		Redefining strategies in treating diabetic dyslipidemia James R. Sowers, MD, FACE, FACP University of Missouri-Columbia
Dec 06 2004 Chicago, Illinois		Translating the trials: Applying evidence-based medicine to clinical practice Elizabeth O. Ofili, MD Morehouse School of Medicine
Nov 19 2004 New York, New York		Optimizing CAD protection: New trial data Howard S. Weintraub, MD New York University School of Medicine
Nov 15 2004 Coral Gables, Florida		Scientific update: LDL and RAAS: The role of oxidative stress and vascular inflammation Arshed A. Quyyumi, MD, FRCP Emory University School of Medicine
Nov 10 2004 Kohler, Wisconsin		Clinical trials update: Role of lipid lowering in blunting the atherosclerotic process Philip R. Liebson, MD, FACC, FACP, FAHA Rush University Medical Center
Nov 01 2004 Philadelphia, Pennsylvania		The new vascular biology mandate for aggressive lipid management Andrew P. Selwyn, MD Harvard Medical School
Oct 14 2004 Los Angeles, California		Vulnerable patient, vulnerable plaque: New scientific insights Arshed A. Quyyumi, MD, FRCP Emory University School of Medicine
Oct 11 2004 New York, New York		Reassessing clinical management of heart failure: New trial data of beta-blockade and RAAS manipulation Ileana L. Piña, MD Case Western Reserve University
Sep 22 2004 Houston, Texas		Multifactorial intervention on macrovascular and microvascular outcomes for diabetes risk reduction: Practical insights and strategies Vivian A. Fonseca, MD Tulane University Health Sciences Center
Sep 21 2004 Seattle, Washington		Clinical trials update: Strategies for multiple risk interventions C. Venkata S. Ram, MD, FACC, MACP University of Texas Southwestern Medical Center at Dallas
Sep 10 2004 Orlando, Florida		Optimizing CAD protection: New trial data Eva M. Lonn, MD, MSc, FRCPC, FACC McMaster University
Aug 16 2004 New York, New York		Clinical trials update: Role of lipid lowering in blunting the atherosclerotic process Jerome D. Cohen, MD, FACC, FACP Saint Louis University School of Medicine
Jun 10 2004 Hershey, Pennsylvania		Vision of a new NCEP: 2004 Robert A. Vogel, MD University of Maryland School of Medicine
May 06 2004 Philadelphia, Pennsylvania		Role of beta-blockade in heart failure: Myths and realities Mark E. Dunlap, MD Case Western Reserve University
Apr 29 2004 Atlanta, Georgia		Clinical trials update: Role of lipid lowering in blunting the atherosclerotic process Robert L. Wilensky, MD, FACC University of Pennsylvania School of Medicine
Apr 27 2004 Fort Lauderdale, Florida		Translating the trials: Applying evidence-based medicine to clinical practice Thomas D. Giles, MD Louisiana State University
Apr 14 2004 Orlando, Florida		Heart failure as an insulin resistance study: Role of RAAS manipulation and beta-blockade Thomas D. Giles, MD Louisiana State University Health Sciences Center
Apr 06 2004 Coral Gables, Florida		New options for anticoagulation: Focus on oral direct thrombin inhibition Albert L. Waldo, MD Case Western Reserve University
Mar 24 2004 Washington, DC		Clinical trials update: Role of lipid lowering in blunting the atherosclerotic process Michael Miller, MD University of Maryland School of Medicine
Mar 23 2004 New York, New York		Mechanistic and scientific insights on atrial fibrillation, thrombosis, and stroke Gerald V. Naccarelli, MD Penn State University College of Medicine
Feb 02 2004 Coronado, California		Quality and quantity of LDL-cholesterol: New Insights Andrew P. Selwyn, MD Harvard Medical School
Jan 19 2004 Nashville, Tennessee		Clinical trials update: Role of early statin use in acute coronary syndromes Robert L. Wilensky, MD University of Pennsylvania School of Medicine
Jan 19 2004 Nashville, Tennessee		Quantity and quality of LDL- cholesterol: New insights Douglas E. Vaughan, MD Vanderbilt University School of Medicine
Jan 16 2004 St. Louis, Missouri		Aggressive lipid management in peri-interventional patients Jerome D. Cohen, MD Saint Louis University Medical Center
Jan 16 2004 St. Louis, Missouri		Clinical trials update: Role of early statin use in acute coronary syndromes Lloyd W. Klein, MD Rush Medical College
Sep 19 2003 New York, New York		VBWG Regional Adjunct Faculty Meeting Andrew P. Selwyn, MD Jeffrey J. Popma, MD James R. Sowers, MD, FACP
Jun 02 2003 Dearborn, Michigan		Interventions in Cardiology Study Group James R. Sowers, MD, FACP Robert L. Wilensky, MD John A. Farmer, MD
Apr 26 2003 Bolton Landing, New York		VBWG Regional Adjunct Faculty Meeting Andrew P. Selwyn, MD C. Venkata S. Ram, MD, FACC, MACP Andrew Jay Drexler, MD
Feb 22 2003 Irving, Texas		Interventions in Cardiology Study Group Andrew P. Selwyn, MD Robert E. Heinig, MD


Home \| Literature Update \| Journal Link \| Resources \| Meeting Highlights \| Members \| About VBWG \| Web Links

Contact us at: info@vbwg.org

Privacy Policy

© 1999-2008 Medical Education Consultants, LLC